// App-Quantinova.ai

1277 : Targeting BCL6-Mediated Resistance to BCR-ABL Targeted Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) through the Addition of Histone Deacetylase (HDAC) Inhibitors

Researchers

Presenter

  • Gordon Cohen

Principal Investigators

  • Colleen E. Annesley

  • Rachel E. Rau

  • Shannon Kelley

  • Daniel Magoon

  • Patrick Brown

Medical Centers

  • Pediatric Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD

  • The Scott Department of Urology, Baylor College of Medicine, Houston, TX

  • Pediatric Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Entinostat

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved